From: Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
Characteristic | Subjects N = 155 |
---|---|
Age (years), mean (SD) | 53.7 (13.1) |
Sex, n (%) | |
Male | 104 (67.1) |
Race, n (%) | |
White | 129 (83.2) |
Black/African American | 4 (2.6) |
Other | 3 (1.9) |
Missing | 19 (12.3) |
BMI (kg/m2), mean (SD) | 27.5 (4.9) |
Cause of spasticity, n (%) | |
Ischemic stroke | 87 (56.1) |
Hemorrhagic stroke | 45 (29.0) |
Traumatic brain injury | 11 (7.1) |
Other cerebral vascular disorders | 6 (3.9) |
Brain tumor | 4 (2.6) |
Cerebral palsy | 2 (1.3) |
Time since diagnosis of event leading to spasticity (months), median (range) | |
Left body side; n = 81 | 61.4 (2.8–428.9) |
Right body side; n = 68 | 46.5 (3.7–372.8) |
REPASa score at study baseline, mean (SD) | 24.8 (6.7) |
DASb score at study baseline, mean (SD) | |
Principle therapeutic target | 2.6 (0.5) |
Hygiene | 2.6 (0.5) |
Dressing | 2.6 (0.5) |
Limb position | 2.6 (0.5) |
Pain | 2.8 (0.4) |